Today: 29 April 2026
Browse Category

Biotechnology 12 January 2026 - 16 January 2026

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
16 January 2026
···
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares surged 35% Friday after reporting faster enrollment and positive interim results in its ANKTIVA bladder cancer trial. The company also disclosed $113 million in 2025 preliminary revenue and Saudi approval for ANKTIVA in lung cancer. Shares traded at $5.34 by midday with 133 million shares changing hands. Early data from its CD19 CAR-NK cell therapy showed complete responses in Waldenström lymphoma.
16 January 2026
···
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
···
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals shares rose 10.4% to $38.03 by midday Wednesday after the company announced 2026 targets for its chronic myeloid leukemia drug at the JPMorgan Healthcare Conference. The company plans a pivotal dose selection and an FDA meeting by mid-2026, following early trial data showing a 75% major molecular response at 24 weeks. Investors are watching for longer-term results and regulatory milestones.
14 January 2026
··
KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

Kiniksa shares fell 6.1% to $38.61 Tuesday after the company projected 2026 ARCALYST revenue of $900–$920 million, below the prior year’s growth rate. The drop followed an intraday low of $38.27. Wedbush raised its price target to $50, citing increased prescriber numbers and longer therapy use. Kiniksa reported $677.5 million in 2025 ARCALYST revenue and ended the year with $414.1 million in cash.
13 January 2026
····
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics shares surged about 14% midday Tuesday after a recent SEC filing revealed a $100 million upfront patent license deal with Roche’s Genentech for an oral GLP-1 drug. The stock rose to $79.24, up $9.88 from Monday’s close, as investors re-evaluated obesity-drug makers during the J.P. Morgan Healthcare Conference.
13 January 2026
····
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna shares jumped 11.7% to $37.81 after the company raised its 2025 sales outlook to about $1.9 billion and cut its operating expense forecast by $200 million. The company reiterated its 2026 growth target and said it does not expect flu or COVID-flu shots to be approved for the 2026 season. Investors await Feb. 13 results and early-2026 cancer vaccine data with Merck.
13 January 2026
··
ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio shares rose 6.4% to $2.76 Tuesday after reporting new lung cancer trial data for its drug ANKTIVA. The company said ANKTIVA combined with checkpoint inhibitors restored immune-cell levels in two studies, with one showing longer median survival for patients with higher lymphocyte counts. A Phase 3 trial comparing ANKTIVA to docetaxel is ongoing. Fuller results are pending peer review.
13 January 2026
··
Thermo Fisher (TMO) stock slips after-hours after Nvidia lab-automation tie-up, exec shake-up

Thermo Fisher (TMO) stock slips after-hours after Nvidia lab-automation tie-up, exec shake-up

Thermo Fisher shares fell about 0.5% after hours Monday following news of a partnership with Nvidia on AI-driven lab automation and executive departures. COO Michel Lagarde and EVP Frederick Lowery will leave in early 2026, with Marc Casper set to become chairman and CEO. Lowery will join Henry Schein as CEO in March 2026. Thermo Fisher closed regular trading at $615.45, down 0.6%.
13 January 2026
····
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences shares fell 8.5% to $26.08 in afternoon trading after the company reported preliminary 2025 revenue near $800 million, up 94%, but warned of significant prior-period adjustments. The company also announced a partnership with Everlywell to develop a blood-based early cancer detection test, with more details expected at the JPMorgan Healthcare Conference later Monday.
12 January 2026
··
GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx shares fell about 14% to $115.75 Monday after releasing preliminary 2025 results and 2026 revenue guidance above analyst estimates. The company projected 2026 revenue of $540–$555 million and positive adjusted net income. Investors are awaiting CEO remarks at the Jan. 14 J.P. Morgan Healthcare Conference and the Feb. 23 earnings report for further details. The latest figures remain unaudited and subject to revision.
12 January 2026
·
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio shares fell 17.7% to $6.62 Monday after announcing a licensing deal with Eisai and releasing initial sales data for its lung-cancer drug. Eisai will pay €50 million upfront for rights outside the U.S., China, and Japan, with further milestone payments possible. Fourth-quarter Ibtrozi sales met estimates, but investors appeared cautious on future prescription growth.
12 January 2026
····
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Johnson & Johnson shares rose 2.3% to $209.03 after new data showed its drug Rybrevant, combined with chemotherapy, produced a 51% response rate in metastatic colorectal cancer. The results, from the OrigAMI-1 trial, included a 73% response rate in first-line patients. The company’s fourth-quarter earnings report is due Jan. 21. J&J recently struck a deal with the Trump administration to lower U.S. drug prices.
12 January 2026
···
Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience shares rose nearly 8% Monday after preliminary fiscal Q1 revenue reached about $103.7 million, beating company forecasts. DNA Synthesis and Protein Solutions sales climbed 27% to $51.1 million, while NGS Applications revenue hit $52.6 million. CEO Emily Leproust cited strong demand in both segments. Full audited results are due Feb. 2.
12 January 2026
··
Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna shares fell 4% to $32.92 Monday after the company raised its 2025 revenue forecast to $1.9 billion and projected operating expenses of up to $5.2 billion. CFO Jamey Mock said U.S. retail vaccination rates dropped 26% in 2025. The company expects about $8.1 billion in year-end cash, including $600 million from a new loan. Investors remain cautious as pandemic demand fades and late-stage vaccine trial results approach.
12 January 2026
···
CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology shares surged 29.3% to $54.20 after the company moved up its Phase 3 PIVOT-006 trial timeline, now expecting topline results in early 2026. Trading volume reached 7 million shares. Analysts raised price targets following the update and ahead of the JPMorgan Healthcare Conference. The trial enrolls over 360 bladder cancer patients and measures recurrence-free survival.
12 January 2026
··
1 2 3 4 5 6 … 16

Stock Market Today

  • Micron Technology Stock Outlook to 2030 Amid Soaring AI Memory Demand
    April 28, 2026, 9:37 PM EDT. Micron Technology (MU) has surged 522% in the past year, driven by booming demand for memory chips crucial for AI data centers. The company produces DRAM and NAND flash memory, essential for AI processors handling complex workloads. Industry forecasts suggest a persistent supply shortage through 2030, with data centers expected to consume 70% of global memory production this year. This tight supply-demand balance, supported by limited new factory capacity, positions Micron for sustained growth. Analysts anticipate continued earnings expansion, with fiscal 2025 EPS at $8.29 and potential dips in 2028 viewed as unlikely. Micron's strong footing in the red-hot AI memory market could enable further stock gains by the decade's end.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop